Abstract

Both lytic and apoptotic cell death remove senescent and damaged cells in living organisms. However, they elicit contrasting pro- and anti-inflammatory responses, respectively. The precise cellular mechanism that governs the choice between these two modes of death remains incompletely understood. Here we identify Gasdermin E (GSDME) as a master switch for neutrophil lytic pyroptotic death. The tightly regulated GSDME cleavage and activation in aging neutrophils are mediated by proteinase-3 and caspase-3, leading to pyroptosis. GSDME deficiency does not alter neutrophil overall survival rate; instead, it specifically precludes pyroptosis and skews neutrophil death towards apoptosis, thereby attenuating inflammatory responses due to augmented efferocytosis of apoptotic neutrophils by macrophages. In a clinically relevant acid-aspiration-induced lung injury model, neutrophil-specific deletion of GSDME reduces pulmonary inflammation, facilitates inflammation resolution, and alleviates lung injury. Thus, by controlling the mode of neutrophil death, GSDME dictates host inflammatory outcomes, providing a potential therapeutic target for infectious and inflammatory diseases.

Apoptotic and lytic cell death pathways are both utilised in the removal of damaged cells; however, the downstream inflammatory outcomes widely vary according to the chosen pathway. Here authors show that in mice with genetic deletion of Gasdermin E specifically in neutrophils, these cells undergo apoptosis rather than pyroptotic cell death upon senescence, with consequential attenuation of reactive inflammatory responses.

Details

Title
Gasdermin E dictates inflammatory responses by controlling the mode of neutrophil death
Author
Ma, Fengxia 1   VIAFID ORCID Logo  ; Ghimire, Laxman 2   VIAFID ORCID Logo  ; Ren, Qian 1   VIAFID ORCID Logo  ; Fan, Yuping 1 ; Chen, Tong 1   VIAFID ORCID Logo  ; Balasubramanian, Arumugam 2   VIAFID ORCID Logo  ; Hsu, Alan 2   VIAFID ORCID Logo  ; Liu, Fei 2 ; Yu, Hongbo 3 ; Xie, Xuemei 2 ; Xu, Rong 2 ; Luo, Hongbo R. 2   VIAFID ORCID Logo 

 Chinese Academy of Medical Sciences & Peking Union Medical College, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, CAMS Key Laboratory for Prevention and Control of Hematological Disease Treatment Related Infection, Institute of Hematology & Blood Diseases Hospital, Tianjin, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Chinese Academy of Medical Sciences, Tianjin Institutes of Health Science, Tianjin, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839) 
 Boston Children’s Hospital, Department of Pathology, Dana-Farber/Harvard Cancer Center, PhD Program in Immunology, Harvard Medical School; Department of Laboratory Medicine, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438) 
 VA Boston Healthcare System, Department of Pathology and Laboratory Medicine, West Roxbury, USA (GRID:grid.410370.1) (ISNI:0000 0004 4657 1992) 
Pages
386
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2912141832
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.